Dual-Functional PLGA Nanoparticles Co-Loaded with Indocyanine Green and Resiquimod for Prostate Cancer Treatment

References

• Rawla P. Epidemiology of prostate cancer. World J Oncol. 2019;10(2):63–89. doi:10.14740/wjon1191
   PubMedGoogle Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi:10.3322/caac.21590
   PubMed Web of Science ®Google Scholar
• Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2020.
   Google Scholar
• Cornford P, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol. 2020.
   Google Scholar
• Xu J, Qiu Y. Current opinion and mechanistic interpretation of combination therapy for castration-resistant prostate cancer. Asian J Androl. 2019;21(3):270–278. doi:10.4103/aja.aja_10_19
   PubMedGoogle Scholar
• Boettcher AN, Usman A, Morgans A, VanderWeele DJ, Sosman J, Wu JD. Past, current, and future of immunotherapies for prostate cancer. Front Oncol. 2019;9:884. doi:10.3389/fonc.2019.00884
   PubMed Web of Science ®Google Scholar
• Ahdoot M, Lebastchi AH, Turkbey B, Wood B, Pinto PA. Contemporary treatments in prostate cancer focal therapy. Curr Opin Oncol. 2019;31(3):200–206. doi:10.1097/CCO.0000000000000515
   PubMed Web of Science ®Google Scholar
• Vitkin N, Nersesian S, Siemens DR, Koti M. The tumor immune contexture of prostate cancer. Front Immunol. 2019;10:603. doi:10.3389/fimmu.2019.00603
   PubMed Web of Science ®Google Scholar
• Pan C, Liu H, Robins E, et al. Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy. J Hematol Oncol. 2020;13(1):29. doi:10.1186/s13045-020-00862-w
   PubMed Web of Science ®Google Scholar
• Bouzid R, Peppelenbosch M, Buschow SI. Opportunities for conventional and in situ cancer vaccine strategies and combination with immunotherapy for gastrointestinal cancers, a review. Cancers (Basel). 2020;12(5):1121. doi:10.3390/cancers12051121
   PubMedGoogle Scholar
• Hammerich L, Bhardwaj N, Kohrt HE, Brody JD. In situ vaccination for the treatment of cancer. Immunotherapy. 2016;8(3):315–330. doi:10.2217/imt.15.120
   PubMed Web of Science ®Google Scholar
• Kieffer ME, Patel AM, Hollingsworth SA, Seganish WM. Small molecule agonists of toll-like receptors 7 and 8: a patent review 2014–2020. Expert Opin Ther Pat. 2020;30(11):825–845. doi:10.1080/13543776.2020.1825687
   PubMedGoogle Scholar
• Ilyinskii PO, Roy CJ, O’Neil CP, et al. Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release. Vaccine. 2014;32(24):2882–2895. doi:10.1016/j.vaccine.2014.02.027
   PubMed Web of Science ®Google Scholar
• Pesapane F, Patella F, Fumarola EM, et al. The prostate cancer focal therapy. Gland Surg. 2018;7(2):89–102. doi:10.21037/gs.2017.11.08
   PubMedGoogle Scholar
• Catalona WJ. Prostate cancer screening. Med Clin North Am. 2018;102(2):199–214. doi:10.1016/j.mcna.2017.11.001
   PubMed Web of Science ®Google Scholar
• Lepor H, Gold S, Wysock J. Focal ablation of prostate cancer. Rev Urol. 2018;20(4):145–157. doi:10.3909/riu0809
   PubMedGoogle Scholar
• Reinhart MB, Huntington CR, Blair LJ, Heniford BT, Augenstein VA. Indocyanine green: historical context, current applications, and future considerations. Surg Innov. 2016;23(2):166–175. doi:10.1177/1553350615604053
   PubMed Web of Science ®Google Scholar
• Wang H, Li X, Tse BW, et al. Indocyanine green-incorporating nanoparticles for cancer theranostics. Theranostics. 2018;8(5):1227–1242. doi:10.7150/thno.22872
   PubMed Web of Science ®Google Scholar
• Essa D, Kondiah PPD, Choonara YE, Pillay V. The design of poly(lactide-co-glycolide) nanocarriers for medical applications. Front Bioeng Biotechnol. 2020;8:48. doi:10.3389/fbioe.2020.00048
   PubMed Web of Science ®Google Scholar
• Kim YS, Park JS, Park M, et al. PLGA nanoparticles with multiple modes are a biologically safe nanocarrier for mammalian development and their offspring. Biomaterials. 2018;183:43–53. doi:10.1016/j.biomaterials.2018.08.042
   PubMed Web of Science ®Google Scholar
• Iqbal M, Zafar N, Fessi H, Elaissari A. Double emulsion solvent evaporation techniques used for drug encapsulation. Int J Pharm. 2015;496(2):173–190. doi:10.1016/j.ijpharm.2015.10.057
   PubMed Web of Science ®Google Scholar
• Xu N, Huang L, Li X, et al. The novel combination of nitroxoline and PD-1 blockade, exerts a potent antitumor effect in a mouse model of prostate cancer. Int J Biol Sci. 2019;15(5):919–928. doi:10.7150/ijbs.32259
   PubMedGoogle Scholar
• Xu P, Xu N, Guo K, et al. Real-time monitoring of tumor progression and drug responses in a preclinical mouse model of prostate cancer. Oncotarget. 2016;7(22):33025–33034. doi:10.18632/oncotarget.8846
   PubMedGoogle Scholar
• Ashrafizadeh M, Hushmandi K, Rahmani Moghadam E, et al. Progress in delivery of siRNA-based therapeutics employing nano-vehicles for treatment of prostate cancer. Bioengineering. 2020;7(3). doi:10.3390/bioengineering7030091.
   PubMedGoogle Scholar
• Ashrafizadeh M, Zarrabi A, Hushmandi K, et al. Progress in natural compounds/siRNA co-delivery employing nanovehicles for cancer therapy. ACS Comb Sci. 2020;22(12):669–700. doi:10.1021/acscombsci.0c00099
   PubMed Web of Science ®Google Scholar
• Zhang J, Wang L, You X, Xian T, Wu J, Pang J. Nanoparticle therapy for prostate cancer: overview and perspectives. Curr Top Med Chem. 2019;19(1):57–73. doi:10.2174/1568026619666190125145836
   PubMedGoogle Scholar
• Foroozandeh P, Aziz AA. Insight into cellular uptake and intracellular trafficking of nanoparticles. Nanoscale Res Lett. 2018;13(1):339. doi:10.1186/s11671-018-2728-6
   PubMed Web of Science ®Google Scholar
• Murugan K, Choonara YE, Kumar P, Bijukumar D, Du Toit LC, Pillay V. Parameters and characteristics governing cellular internalization and trans-barrier trafficking of nanostructures. Int J Nanomedicine. 2015;10:2191–2206. doi:10.2147/IJN.S75615
   PubMed Web of Science ®Google Scholar
• Klotz L. Contemporary approach to active surveillance for favorable risk prostate cancer. Asian J Urol. 2019;6(2):146–152. doi:10.1016/j.ajur.2018.12.003
   PubMed Web of Science ®Google Scholar
• Liu B, Li C, Cheng Z, Hou Z, Huang S, Lin J. Functional nanomaterials for near-infrared-triggered cancer therapy. Biomater Sci. 2016;4(6):890–909. doi:10.1039/C6BM00076B
   PubMed Web of Science ®Google Scholar
• Zhou Y, Liu S, Hu C, Cai L, Pang M. A covalent organic framework as a nanocarrier for synergistic phototherapy and immunotherapy. J Mater Chem B. 2020;8(25):5451–5459. doi:10.1039/D0TB00679C
   PubMedGoogle Scholar
• Xu P, Liang F. Nanomaterial-based tumor photothermal immunotherapy. Int J Nanomedicine. 2020;15:9159–9180. doi:10.2147/IJN.S249252
   PubMed Web of Science ®Google Scholar
• Nomura S, Morimoto Y, Tsujimoto H, et al. Highly reliable, targeted photothermal cancer therapy combined with thermal dosimetry using a near-infrared absorbent. Sci Rep. 2020;10(1):9765. doi:10.1038/s41598-020-66646-x
   PubMed Web of Science ®Google Scholar
• Zheng M, Yue C, Ma Y, et al. Single-step assembly of DOX/ICG loaded lipid–polymer nanoparticles for highly effective chemo-photothermal combination therapy. ACS Nano. 2013;7(3):2056–2067. doi:10.1021/nn400334y
   PubMed Web of Science ®Google Scholar
• Zou L, Wang H, He B, et al. Current approaches of photothermal therapy in treating cancer metastasis with nanotherapeutics. Theranostics. 2016;6(6):762–772. doi:10.7150/thno.14988
   PubMed Web of Science ®Google Scholar
• Xu X, Lu H, Lee R. Near infrared light triggered photo/immuno-therapy toward cancers. Front Bioeng Biotechnol. 2020;8:488. doi:10.3389/fbioe.2020.00488
   PubMed Web of Science ®Google Scholar
• Chen Q, Xu L, Liang C, Wang C, Peng R, Liu Z. Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy. Nat Commun. 2016;7(1):13193. doi:10.1038/ncomms13193
   PubMed Web of Science ®Google Scholar
• Sadeghi I, Byrne J, Shakur R, Langer R. Engineered drug delivery devices to address global health challenges. J Control Release. 2021;331:503–514. doi:10.1016/j.jconrel.2021.01.035
   PubMed Web of Science ®Google Scholar
• Liu Z, Xie Y, Xiong Y, et al. TLR 7/8 agonist reverses oxaliplatin resistance in colorectal cancer via directing the myeloid-derived suppressor cells to tumoricidal M1-macrophages. Cancer Lett. 2020;469:173–185. doi:10.1016/j.canlet.2019.10.020
   PubMed Web of Science ®Google Scholar
• Rodell CB, Arlauckas SP, Cuccarese MF, et al. TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy. Nat Biomed Eng. 2018;2(8):578–588. doi:10.1038/s41551-018-0236-8
   PubMed Web of Science ®Google Scholar
• Chen PM, Pan WY, Wu CY, et al. Modulation of tumor microenvironment using a TLR-7/8 agonist-loaded nanoparticle system that exerts low-temperature hyperthermia and immunotherapy for in situ cancer vaccination. Biomaterials. 2020;230:119629. doi:10.1016/j.biomaterials.2019.119629
   PubMed Web of Science ®Google Scholar
• Kim H, Khanna V, Kucaba TA, et al. TLR7/8 agonist-loaded nanoparticles augment NK cell-mediated antibody-based cancer immunotherapy. Mol Pharm. 2020;17(6):2109–2124. doi:10.1021/acs.molpharmaceut.0c00271
   PubMedGoogle Scholar
• Kim H, Griffith TS, Panyam J. Poly(d,l-lactide-co-glycolide) nanoparticles as delivery platforms for TLR7/8 agonist-based cancer vaccine. J Pharmacol Exp Ther. 2019;370(3):715–724. doi:10.1124/jpet.118.254953
   PubMedGoogle Scholar
• Ferlazzo G, Morandi B. Cross-talks between natural killer cells and distinct subsets of dendritic cells. Front Immunol. 2014;5:159. doi:10.3389/fimmu.2014.00159
   PubMed Web of Science ®Google Scholar
• Bottcher JP, Bonavita E, Chakravarty P, et al. NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. Cell. 2018;172(5):1022–1037e1014. doi:10.1016/j.cell.2018.01.004
   PubMed Web of Science ®Google Scholar
• Michaelis KA, Norgard MA, Levasseur PR, et al. Persistent toll-like receptor 7 stimulation induces behavioral and molecular innate immune tolerance. Brain Behav Immun. 2019;82:338–353. doi:10.1016/j.bbi.2019.09.004
   PubMedGoogle Scholar
• Islam MA, Rice J, Reesor E, et al. Adjuvant-pulsed mRNA vaccine nanoparticle for immunoprophylactic and therapeutic tumor suppression in mice. Biomaterials. 2021;266:120431. doi:10.1016/j.biomaterials.2020.120431
   PubMed Web of Science ®Google Scholar
• Girometti R, Cereser L, Bonato F, Zuiani C. Evolution of prostate MRI: from multiparametric standard to less-is-better and different-is better strategies. Eur Radiol Exp. 2019;3(1):5. doi:10.1186/s41747-019-0088-3
   PubMedGoogle Scholar
• Connor MJ, Gorin MA, Ahmed HU, Nigam R. Focal therapy for localized prostate cancer in the era of routine multi-parametric MRI. Prostate Cancer Prostatic Dis. 2020;23(2):232–243. doi:10.1038/s41391-020-0206-6
   PubMedGoogle Scholar